GI Innovation Inc
KOSDAQ:358570
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
Vinacomin Coal Import Export JSC
VN:CLM
|
VN |
|
Ecovyst Inc
NYSE:ECVT
|
US |
|
HMT Ltd
NSE:HMT
|
IN |
GI Innovation Inc
Other
GI Innovation Inc
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
GI Innovation Inc
KOSDAQ:358570
|
Other
-₩140.1m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Other
₩1.5T
|
CAGR 3-Years
163%
|
CAGR 5-Years
41%
|
CAGR 10-Years
28%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Other
-₩539.2m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-58%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Other
-₩23m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Other
-₩50.5m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
GI Innovation Inc
Glance View
GI Innovation, Inc. engages in the development of biopharmaceutical products. The company is headquartered in Seoul, Seoul and currently employs 88 full-time employees. The company went IPO on 2023-03-30. The firm is engaged in the business of generating revenue through license fees by technology transfer of new drug candidates in pre-clinical and early clinical stages. The core new drug pipeline includes products such as GI-101 immuno-oncology and GI-301 allergy treatment.
See Also
What is GI Innovation Inc's Other?
Other
-140.1m
KRW
Based on the financial report for Dec 31, 2024, GI Innovation Inc's Other amounts to -140.1m KRW.
What is GI Innovation Inc's Other growth rate?
Other CAGR 3Y
-31%
Over the last year, the Other growth was 83%. The average annual Other growth rates for GI Innovation Inc have been -31% over the past three years .
